

ASTS Statement on donor derived cell-free DNA (dd-cfDNA) – Updated October 2024

Definition of the Problem:

The goal of organ transplantation is to save lives and increase quality of life. The pressing strategic goals for the transplant community are to increase the number of patients receiving transplants, improve access to transplantation for all, and improve long term transplant outcomes. Improving long term transplant outcomes gets less attention than those first two goals but is central to achieving those strategic imperatives because better long term allograft survival will lead to fewer candidates returning to the waiting list. Despite enormous success in other phases of the transplant endeavor, dramatic improvements in long term allograft survival have proven elusive. One of the key reasons for this may be that the transplant community continues to monitor allograft function utilizing decades-old legacy modalities. For example, in the case of renal allograft function, clinicians still rely primarily on monitoring serum creatinine, urine protein, and donor specific antibody. The emergence of molecular diagnostic techniques has the potential to alter that paradigm and may allow significant improvements in long term allograft function. Our goals in commenting on this topic are to provide clarity for clinicians regarding the clinical rationale and appropriate utilization of these tests and to advocate for access to these modalities as clinically appropriate for the patients we serve.

The role of donor derived cell-free DNA (dd-cfDNA) in kidney transplant surveillance:

Perhaps the largest unmet need for which molecular diagnostics may play a role is in the surveillance of kidney transplant recipients for rejection or allograft injury. That population of patients is large, legacy surveillance techniques are limited in efficacy, and improvements in long-term kidney allograft survival have proven elusive despite years of effort and substantial improvements in short-term allograft survival. The clinical utility provided by dd-cfDNA is highlighted by the findings of several key studies:

The Circulating Donor-Derived Cell-Free DNA in blood for diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study assessed 1272 samples from 384 unique kidney recipients from 14 clinical sites. In the DART study, Bloom et al reported that dd-cfDNA was a better discriminator of acute rejection than serum creatinine, with median levels of dd-cfDNA in recipients with active rejection significantly higher (1.6%) than in those without active rejection (0.3%). A dd-cfDNA threshold of 1.0% yielded 85% specificity and 59% sensitivity to discriminate active rejection from the absence of rejection. At a 1.0% dd-cfDNA threshold, PPV was 61% and NPV was 84%. Furthermore, at a dd-cfDNA threshold of <0.21%, NPV for acute rejection was 95% (Bloom et al, 2017).

Jordan et al found that elevated dd-cfDNA levels are associated with increased likelihood of de novo DSA development in kidney recipients. They also demonstrated that dd-cfDNA levels above a threshold of 2.9%, in conjunction with a positive DSA, confer an 89% PPV for ABMR (Jordan et al. 2018).



ASTS

American Society of
Transplant Surgeons

Stites et al evaluated the ability of elevations of dd-cfDNA to predict the clinical course of kidney recipients with the finding of TCMR 1A or Borderline acute rejection on biopsy. They discovered that a dd-cfDNA level over 0.5% predicted longitudinal eGFR decline over the following 6-months, while those kidney recipients with the same biopsy findings but a dd-cfDNA level \leq 0.5% did not have evidence of eGFR decline during the 6-month period of study follow-up. Notably, the patients with dd-cfDNA levels $>$ 0.5% and a biopsy finding of TCMR 1A or Borderline TCMAR at study entry had a 40.5% likelihood of de novo DSA development and 21.5% likelihood of development of recurrent AR during the study follow-up. In contrast, those with dd-cfDNA levels less than or equal to 0.5% experienced a 2.7% likelihood of development of de novo DSA and 0% likelihood of recurrent AR.

Bu et al published the findings of the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study in 2021. This large (1092 kidney transplant recipients), multi-institutional cohort study validated many areas of clinical utility for dd-cfDNA in renal transplant recipients and confirmed the relationship between acute rejection and dd-cfDNA levels elucidated in the DART study. Data from this study builds on prior work to demonstrate areas of clinical decision utility for dd-cfDNA, some of which are briefly reviewed below.

Aubert et al found that dd-cfDNA levels strongly correlated with allograft rejection and had a high predictive value for the detection of subclinical rejection. This was demonstrated in a derivation cohort of over 1,100 transplant patients at 2 Parisian transplant centers and confirmed in a validation cohort of over 1,700 patients at 11 transplant centers in the US and 1 transplant center in Belgium). The inclusion of dd-cfDNA improved the predictive ability of a model for the detection of kidney allograft rejection independent of other standard of care markers.

Relationship of dd-cfDNA and acute rejection:

Bu et confirmed that dd-cfDNA is a significantly better ($P < 0.001$) discriminator of rejection than serum creatinine, with the AUROC for creatinine in prediction of rejection being 0.495 (95% CI; 0.38-0.59), while the AUROC for dd-cfDNA was 0.798 (95% CI; 0.72-0.87). In the 1092 patients studied, dd-cfDNA results also stratified for type of rejection, with the dd-cfDNA result in ABMR having a median of 1.8%, in TCMR a median of 0.7%, and in no rejection a median of 0.23%. The authors reported that a 1% increase in dd-cfDNA level was associated with a 3.3-fold increase in the likelihood of rejection diagnosis ($P < 0.001$), and with a hazard ratio for rejection of 1.89 (95% CI; 1.78-2.1).

Aubert et al demonstrated that dd-cfDNA levels increased with the severity of renal allograft microcirculatory inflammation, C4d deposition, tubulitis, interstitial inflammation and total inflammation noted on histologic examination of biopsy specimens. Levels of dd-cfDNA were also shown to remain elevated in patients with ongoing rejection ($P = 0.002$), and to decrease in patients with biopsy proven resolution of rejection ($P < 0.001$) on repeat renal allograft biopsies.

Relationship of dd-cfDNA and longitudinal eGFR decline:

Bu et al analyzed dd-cfDNA levels and renal function from year one to year three after kidney transplantation and found that a dd-cfDNA level > 0.5% was associated with significant eGFR decline at three-years post-transplant. Furthermore, persistently (> 1 value) elevated (>0.5%) dd-cfDNA levels almost doubled (HR 1.97) the risk of a 25% decline in eGFR (95% CI; 1.39-2.68, P = 0.041).

Relationship of dd-cfDNA and de novo DSA development:

In the ADMIRAL study, Bu et al evaluated 961 patients with paired dd-cfDNA and DSA results, none of whom had preexisting DSA at study entry. The authors found that dd-cfDNA levels >0.5% almost tripled (HR 2.71, P = 0.001) the likelihood of future de novo DSA development. In multivariable analysis, each 1% increase in dd-cfDNA levels was associated with a 20% higher likelihood of subsequent de novo DSA development (HR 1.19; P = 0.004). Interestingly, the increases in dd-cfDNA occurred a median of 91 days prior to the detection of de novo DSA, suggesting that, much as it is for serum creatinine, dd-cfDNA is a leading, rather than a lagging indicator of DSA development.

Relationship of dd-cfDNA and renal allograft injury:

The ADMIRAL study utilized a composite allograft injury metric to assess dd-cfDNA levels in injured and what were termed quiescent allografts. The composite score included those recipients with BK viremia, urinary tract infection, rejection, de novo DSA, proteinuria and recurrent FSGS. Recipients without any of these criteria were termed quiescent. The median dd-cfDNA level in those meeting injury criteria was 0.51% (95% CI; 0.48-1.2%), and the median dd-cfDNA level in those without criteria for allograft injury (those deemed quiescent) was 0.21% (95% CI; 0.19-0.34). The difference in median values was highly statistically significant (P <0.0001). The dd-cfDNA scores in the quiescent group mirrored that of the stable kidney recipients from the multicenter DART study and reaffirmed the typical low dd-cfDNA levels seen in stable allograft recipients. In ADMIRAL, the AUROC for dd-cfDNA to predict injury versus quiescence was 0.727 (95% CI; 0.71-0.88), while the AUROC for creatinine was only 0.575 (95% CI; 0.52-0.62). The median creatinine in quiescent patients was 1.32 mg/dl (95% CI; 1.16-1.65), while in those with allograft injury, the median creatinine was 1.48 (95% CI; 1.1-2.7) (P = 0.08). Thus, creatinine was not able to effectively discriminate the allograft injury recipients from the quiescent allograft recipients, while dd-cfDNA assessment was.

Recommendations on the frequency of surveillance testing in kidney transplant recipients

Prospective trials designed to optimize the frequency of dd-cfDNA testing in stable, asymptomatic adult renal transplant recipients are lacking, and obtaining such data may prove impractical. However, the evidence for the clinical utility of dd-cfDNA surveillance testing is clear, as is the utility of testing longitudinally. However, the optimal surveillance testing frequency is unknown. The



ASTS

American Society of
Transplant Surgeons

most robust clinical validation study for surveillance testing comes from the DART study, which utilized the so-called “ARTS” surveillance testing schedule. This protocol recommended testing at monthly intervals from month 1-4, and then quarterly thereafter.

This schedule was developed empirically based on the KDIGO recommended testing frequencies for other noninvasive post-transplant test and focused the most frequent testing at the time of highest immunologic risk and the most kinetic portion of the post-transplant period and then decreased frequencies later in the post-transplant course. Importantly, longitudinal surveillance testing at this frequency will provide an early baseline pattern for the allograft and then capture data at critical post-transplant immunologic timepoints. Important timepoints leading to possible increases in allograft injury include periods of steroid weaning, decreasing CNI trough level goals, and the waning of the immunologic effect of induction therapy.

There are no data to support testing prior to one-month post-transplant. There are no data to support cessation of surveillance testing at any timepoint after transplant, and it is intuitively obvious that, as the risk of allograft injury or acute rejection does not disappear, testing should continue indefinitely at some frequency. There are no data to support surveillance testing at frequencies greater than the ARTS protocol, and we recommend that providers and programs have protocols in place to prevent obtaining surveillance testing at frequencies greater than the ARTS protocol.

It is important to note that the above discussion refers to surveillance testing, and that clinical findings creating an indication for for-cause testing would not fall under the rubric of protocolized surveillance testing frequencies. It is also important to note that surveillance testing frequencies could arguably differ based on *a priori* immunologic risk, with higher immunologic risk recipients undergoing more frequent testing and low-risk recipients undergoing less frequent testing.

Summary of the role of dd-cfDNA in kidney recipient surveillance:

Collectively, these and other data point to the clinical utility of dd-cfDNA in clinical decision-making in kidney transplant recipients in both the surveillance and for-cause settings. Low dd-cfDNA levels providing robust evidence of immune quiescence and provide the ability to forego unnecessary biopsies, while moderately elevated or rising levels signal a markedly elevated risk of rejection, and high levels provide a high degree of confidence in the presence of underlying antibody mediated rejection (ABMR). High dd-cfDNA levels also signal a markedly elevated risk of both TCMR and ABMR based on the findings of Aubert et al. The demonstrated clinical utility of dd-cfDNA includes a significant improvement relative to serum creatinine measurement in the detection of both TCMR and ABMR. Levels of dd-cfDNA provide a leading indicator of allograft injury, allowing earlier detection of allograft injury than de novo DSA and serum creatinine, and may also serve as a marker for the durability of response to rejection treatment. Additional investigation is needed to clarify the appropriate clinical intervention versus close observation and continued monitoring, especially in recipients with stable graft function, when elevated dd-cfDNA levels are initially encountered. Further research is needed to determine the optimal frequency of surveillance testing utilizing dd-cfDNA to improve long term allograft outcomes.



ASTS

American Society of
Transplant Surgeons

SOCIETY RECOMMENDATIONS REGARDING CLINICAL UTILITY AND DECISION ANALYSIS:

The most data have been accumulated in adult transplant recipients, and these recommendations are therefore most applicable to adult patient populations.

We suggest that clinicians consider measuring serial dd-cfDNA levels in kidney transplant recipients with stable renal allograft function to exclude the presence of subclinical antibody mediated rejection.

We recommend that clinicians measure dd-cfDNA levels in kidney transplant recipients with acute allograft dysfunction to exclude the presence of rejection, particularly antibody-mediated rejection (ABMR).

We do not recommend the use of blood gene expression profiling (GEP) in kidney transplant recipients for the purpose of diagnosing or excluding sub-clinical rejection, as adequate evidence supporting such use is still lacking.

We do not recommend the use of blood GEP to diagnose or exclude the presence of acute graft rejection in kidney transplant recipients with acute allograft dysfunction given the paucity of data to support this practice.

We recommend that dd-cfDNA may be utilized to rule out subclinical rejection in heart transplant recipients.

We recommend that clinicians choosing to utilize dd-cfDNA in heart transplant recipients also utilize peripheral blood GEP as a non-invasive diagnostic tool to rule out acute cellular rejection in stable, low-risk, adult heart transplant recipients who are over 55 days status post heart transplantation.

We recommend that there is still insufficient evidence to recommend dd-cfDNA or GEP testing in liver transplant recipients.

CAVEATS AND RECOMMENDATIONS FOR FUTURE STUDIES

None of these recommendations should be construed as recommending one biomarker over another in the same diagnostic niche.

We strongly recommend ongoing further clinical studies to clarify the scenarios and frequency in which molecular diagnostic studies should be utilized.

We specifically recommend that studies be carried out to evaluate the potential role of dd-cfDNA surveillance in kidney transplant recipients to improve long term allograft survival.

We recommend studies be carried out to evaluate the potential global cost effectiveness of clinical use of dd-cfDNA testing in surveillance and for-cause settings.

PAYER REIMBURSEMENT

We strongly encourage commercial payers to align reimbursement practices for molecular diagnostic testing with clinical guidelines and emerging practice patterns, as well as with Medicare beneficiary coverage patterns.

Summary:

The accumulated evidence supporting the use of dd-cfDNA argues that its use should no longer be considered investigational. The use of dd-cfDNA is evidence-based and validated, and a prime example of much needed innovation in transplant organ surveillance. It has demonstrated utility in the early detection of allograft injury and assistance with clinical decision-making regarding allograft biopsy and treatment initiation. Salient factors that argue for the utilization of dd-cfDNA as a surveillance and for-cause diagnostic modality include:

- Medicare beneficiaries with renal transplants have dd-cfDNA as a covered benefit. This technology is widely used in the MC patient population yet not covered by most commercial payers. This disparity in access is concerning.
- Long term outcomes for kidney recipients are suboptimal. Approximately 20% of allografts fail by 5 years after transplantation. Those allograft losses are bad for patients, bad for payers, and worsen the supply-demand mismatch for kidney transplants because many of those patients ultimately undergo repeat transplantation. Better long-term renal allograft survival is a key that will unlock global cost savings and facilitate transplanting more patients.
- Transplant providers have been managing post-kidney transplant surveillance in much the same way for decades, and innovation and adoption of new tools are needed to improve long-term outcomes. Creatinine is an insensitive marker of allograft injury, and is essentially a lagging indicator of allograft dysfunction, particularly when initial renal function is good. The dependence on creatinine measurement and renal allograft biopsy in the detection of renal allograft injury one of reluctant necessity born of a paucity of better options. The emergence of dd-cfDNA provides a better, and clinically useful, marker of allograft injury that can directly impact patient care and outcomes.
- The rapidly emerging technology of dd-cfDNA provides a validated, evidence-based means to improve the surveillance of renal allografts. Taken as a whole, this technology is being widely adopted by the transplant community and appears useful in both detection of allograft injury and, via a high negative predictive value of low dd-cfDNA levels for underlying rejection, may also prevent unnecessary renal allograft biopsies with their attendant cost and potential morbidity.



ASTS

American Society of
Transplant Surgeons

- Renal allograft failure and return to dialysis is a disaster for individual patients, and enormously expensive for payers.
 - Allograft failure is associated with approximately \$78,079 in additional costs in the first year of return to dialysis.
 - Long-term patient survival is much better with allograft function relative to return to dialysis.

Renal transplantation is a life-saving intervention that is also cost-effective relative to maintenance dialysis. Utilizing biomarkers, particularly dd-cfDNA, for detection of renal allograft injury is an emerging standard of care that can directly aid in clinical decision making that may improve long-term patient and allograft survival. We support access of transplant recipients to these promising diagnostic technologies and advocate for ongoing study of these tools to clarify their utility and cost effectiveness.



ASTS

American Society of
Transplant Surgeons

Selected References:

- 1). Jordan SC, Bunnapradist S, Bromberg JS, et al. Donor-derived cell-free DNA identifies antibody-mediated rejection in donor specific antibody positive kidney transplant recipients. *Transplant Direct*. 2018. Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133406/>.
- 2). Bu L, Gupta G, Pai A, et al. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. *Clinical Investigation*. 2021;101:793-803.
- 3). Pai A, Swan JT, Wojciechowski D, et al. *Ann Transplant*. 2021;26:e932249. 2021 Jul 2. doi:10.12659/AOT.932249
- 4). Hart A, Lentine KL, Smith JM, Miller JM et al. OPTN/SRTR 2019 Annual Data Report: Kidney. *Am J Transplant*. 2021;2:21-137. Doi:10.1111/ajt.16502
- 5). Botev R, Mallie JP, Couchoud C, et al. Estimating Glomerular Filtration Rate: Cockcroft-Gault and Modification of Diet in Renal Disease Formulas Compared to Renal Inulin Clearance. *Clin J Am Soc Nephrol* 4: 899–906, 2009. doi: 10.2215/CJN.05371008
- 6). Bromberg JS, Brennan DC, Poggio E, et al. *J Applied Laboratory Medicine*; 2017. 2(3):309-321
- 7). Grskovic M, Hiller D, Eubank L, et al. Validation of a Clinical-Grade Assay to Measure Donor-Derived Cell-Free DNA in Solid Organ Transplant Recipients. *J Mol Diagn*. 2016 Nov;18(6):890-902. doi: 10.1016/j.jmoldx.2016.07.003. PMID 27727019.
- 8). Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. *JASN*. 2017;28:2221-2232.
- 9). Wolf-Doty TK, Mannon RB, Poggio ED, et al. Dynamic response of donor-derived cell-free DNA following treatment of acute rejection in kidney allografts. *Kidney360*. 2021. <https://doi.org/10.34067/KID.000004202110>
- 10). Martuszewski A, Paluszkiewicz P, Krol M, et al. Donor-derived cell-free DNA in kidney transplantation as a potential rejection biomarker: a systematic literature review. *J Clin Med*. 2021;10:193
- 11). Knight SR, Thorne A, Lo Faro ML. Donor-specific cell-free DNA as a biomarker in solid organ transplantation: a systematic review. *Transplantation*. 2019;103:273-283.
- 12). Stites E, Kumar D, Olaitan O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. *Am J Transplant*. 2020;20:2491-2498 PMID 32056331.
- 13). Kant S, Bromberg J, Haas M, Brennan D. Donor-derived cell-free DNA and the prediction of BK virus-associated nephropathy. *Transplant Direct*. 2020;6:e622.



ASTS

American Society of
Transplant Surgeons

- 14). Huang E, Gillespie M, Ammerman N, et al. Donor-derived cell-free DNA combined with histology improves prediction of estimated glomerular filtration rate over time in kidney transplant recipients compared with histology alone. *Transplant Direct*. 2020;6:e580.
- 15). Seeto RK, Fleming JN, Dholakia S, Dale BL. Understanding and using AlloSure donor derived cell-free DNA. *Biophysical Reviews* (2020) 12:917-924 <https://doi.org/10.1007/s12551-020-00713-5>
- 16). Hinojosa RJ, Chaffin K, Gillespie M, et al. Donor-derived cell-free DNA may confirm real-time response to treatment of acute rejection in renal transplant recipients. *Transplantation*. 2019;103:e61.
- 17). Agbor-Enoh S, Chan JL, Singh A, et al. Late manifestation of alloantibody-associated injury and clinical pulmonary antibody-mediated rejection: evidence from cell-free DNA analysis. *J Heart Lung Transplant*. 2018;37:925-932.
- 18). Agbor-Enoh S, Shah P, Tunc I, et al. Cell-free DNA to detect heart allograft acute rejection. *Circulation*. 2021;143:1184-1197.
- 19). Axelrod D, Schnitzler M, et al. An economic assessment of contemporary kidney transplant practice. *Am J Transplant*. 2018;18:1168-1176. PMID 29451350.
- 20). Yen E, Hardinger K, Brennan D, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. *Am J Transplant*. 2004;4(10):1703-1708
- 21). GAO report to Congressional Requesters. End-stage renal disease. Characteristics of kidney transplant recipients, frequency of transplant failures, and cost to Medicare. 2007. GAO-07-1117.
- 22). Oellerich M, Shipkova M, Asendorf T, et al. Absolute quantification of donor-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study. *Am J Transplant*. 2019; 19(11):3087-3099.
- 23). Obrișcă B, Butiu M, Sibulesky L, Bakthavatsalam R, Smith KD, Gimferrer I, Warner P, Ismail G, Leca N. Combining donor-derived cell-free DNA and donor specific antibody testing as non-invasive biomarkers for rejection in kidney transplantation. *Sci Rep*. 2022 Sep 5;12(1):15061. doi: 10.1038/s41598-022-19017-7. PMID: 36064740; PMCID: PMC9445050.
- 24). Halloran PF, Reeve J, Madill-Thomsen KS, Demko Z, Prewett A, Billings P; Trifecta Investigators. The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies. *J Am Soc Nephrol*. 2022 Feb;33(2):387-400. doi: 10.1681/ASN.2021091191. Epub 2022 Jan 20. PMID: 35058354; PMCID: PMC8819982.
- 25). Gupta, Gaurav & Moinuddin, Irfan & Kamal, Layla & King, Anne & Winstead, Ryan & Demehin, Moses & Kang, Le & Kimball, Pam & Levy, Marlon & Bhati, Chandra & Massey, H & Kumar, Dhiren & Halloran, Philip. (2021). Correlation of Donor-Derived Cell-free DNA with Histology and Molecular



ASTS

American Society of
Transplant Surgeons

Diagnoses of Kidney Transplant Biopsies. *Transplantation*. Publish Ahead of Print.
10.1097/TP.0000000000003838.

26). Henricksen EJ, Moayed Y, Purewal S, Twiggs JV, Waddell K, Luikart H, Han J, Feng K, Wayda B, Lee R, Shudo Y, Jimenez S, Khush KK, Teuteberg JJ. Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation. *Clin Transplant*. 2022 May 12:e14699. doi: 10.1111/ctr.14699. Epub ahead of print. PMID: 35559582.

27). Amadio JM, Rodenas-Alesina E, Superina S, Kozuszko S, Tsang K, Simard A, Aleksova N, Kobulnik J, Fan CS, Wijeyesundera HC, Ross HJ, McDonald MA, Duero Posada JG, Moayed Y. Sparing the Prod: Providing an Alternative to Endomyocardial Biopsies With Noninvasive Surveillance After Heart Transplantation During COVID-19. *CJC Open*. 2022 May;4(5):479-487. doi: 10.1016/j.cjco.2022.02.002. Epub 2022 Feb 13. PMID: 35187463; PMCID: PMC8842090.

28). Gondi KT, Kao A, Linard J, Austin BA, Everley MP, Fendler TJ, Khumri T, Lawhorn SL, Magalski A, Nassif ME, Sperry BW, Vodnala D, Borkon AM. Single-center utilization of donor-derived cell-free DNA testing in the management of heart transplant patients. *Clin Transplant*. 2021 May;35(5):e14258. doi: 10.1111/ctr.14258. Epub 2021 Mar 11. PMID: 33606316.

29). Khush K, Patel J, Pinney S, Kao A, et al. Noninvasive detection of graft injury after heart transplant using donor-derived cell-free DNA: a prospective multicenter study. *Am J Transplant*. 2019;19:2889-2899

30). Keller M, Sun J, Mutebi C, Shah P, et al. Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care. *J Heart Lung Transplant*. 2022; 41(4):458-466

31). Aubert, O., Ursule-Dufait, C., Brousse, R. *et al.* Cell-free DNA for the detection of kidney allograft rejection. *Nat Med*. 2024; **30**:2320–2327.